Helicobacter Pylori and Proton Pump Inhibitor

Asan Medical Center30 enrolled

Overview

The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.

Endoscopy and biopsy will be performed to investigate the distrubition of HP before, during, and after using PPI.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Helicobacter Infections

Interventions

PPI (proton pump inhibitor)DRUG

1. Pre ESD (endoscopic submucosal dissection) * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori * Use of PPI for 2 months 2. Post ESD 1 (After 2 months) * Assess the distribution of helicobacter pylori after using PPI. * Stop of PPI 3. Post ESD 2 (After 4 months) * Assess the distribution of helicobacter pylori after stop of PPI.

Eligibility

Sex: ALLMin age: 19 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients who are indicated to endoscopic resection due to gastric neoplasm 2. Aged between 19 to 65 years 3. Informed consent Exclusion Criteria: 1. Previous history of HP eradication 2. Previous history of PPI use within 6 months 3. No HP infection

Locations (1)

Asan Medical Center

Seoul, Songpa-gu, South Korea

Outcomes

Primary Outcomes

Analysis the change of Helicobacter pylori distribution according to the use of proton pump inhibitor

Time frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.

Secondary Outcomes

Analysis the change of HP distribution according to the use of PPI in atrophic change of stomach

Time frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.